By Brinter Ltd.
To get in touch with Brinter Ltd., simply fill out the form below.
Subscribe to Supplier
Brinter Raises €1.2M in Seed Funding for 3D Printing Bioscience platform
Turku, Finland: – Pioneering modular multi-material bioprinting platform developer and manufacturer, Brinter, has announced the successful closure of a €1.2M seed funding round led by early-stage Venture Capital (VC) specialist Innovestor.
The company will use the capital to further expand its operations internationally in Europe and the US. Brinter aims to put bioprinting within reach of every pharmaceutical company, hospital, university, and research center.
The 3D bioprinting market is growing strongly as accelerated technological, material, and methodological developments expand the range of potential applications. Brinter believes it can speed up scientific development in this sector up to tenfold.
Medical research facilities and universities often still rely on traditional methods of discovery in the research of new drugs and therapies. Brinter’s modular multi-material 3D bioprinting solution offers a premium yet cost-effective approach to accelerate and streamline the scientific discovery process and bio-manufacturing, with almost unlimited potential to scale as technologies develop.
Brinter aims to remove technology as a limitation to improving quality of life. The company also seeks to save more lives through more personalized treatment and the production of “spare parts” such as hearts and kidneys.
Bioprinted spare parts for humans
“Bioprinting has the capability to rapidly unlock the opportunities behind long-running but unrealized science and research, and plays a key role in pushing the frontier of medical science. This will result in an improved quality of life for patients through the expansion of more personalized treatment and the ongoing development of bioprinted “spare parts” that can save lives,” says Brinter CEO Tomi Kalpio.
“We are excited to have the backing of Innovestor who can help us accelerate the development of our operational capabilities and scale in new geographies,” Mr. Kalpio added.
Customized hearts and kidneys
Innovestor CEO Wilhelm Lindholm commented: “Companies like Brinter are paving the way for 3D bioprinting, revolutionizing the future of medicine to the point where a customized heart or kidney can be made for a transplant patient.”
“We are very excited to be a part of Brinter’s journey. Brinter is an exciting addition to our portfolio as it not only fits in our focus areas of industrial and health technologies, but the company’s competitive advantages of multi-material printing capabilities, modularity, and scalability combined with their own easy-to-use software application were very convincing,” Mr. Lindholm declared.
“The printing of a new kidney for a transplant patient from programmed stem cells is a highly promising opportunity and could be realized already within this decade,” estimates Professor Seppo Vainio, Research Director of the University of Oulu’s Kvantum Institute of Developmental Biology.
“There is a worldwide need for kidney transplants due to the rising incidence of diabetes, for example. Even the COVID-19 disease can lead to acute kidney failure, so there’s a great need for printed organ transplants and we look forward to the achievements that we will be able to reach using Brinter,” said Prof. Vainio.
Dr. Jari Koistinaho, Director of the Neuroscience Center at the University of Helsinki, believes 3D bioprinting also has potential in Neuropharmacology.
“I am extremely excited to continue our 3D brain printing project with Brinter. The brain is an extremely vulnerable organ and target of various incurable diseases with the highest societal impact. Combined with two other rapidly-developing technologies – stem cells and biomaterials – 3D-bioprinting will soon provide us with fine-tuned human mini-brains and brain prosthetics, thereby deepening our understanding of the human mind and our ability to combat serious brain disorders,” said Dr. Koistinaho.
Founded in 2020 via partial demerger in Turku, Finland, Brinter is a modular multi-material bioprinting platform scalable from manual R&D to automated production. The company works with science and bioengineering organizations to integrate 3D bioprinting into their research, manufacturing, and treatment methods. The goal is to break through current technological limitations and improve people’s quality of life.
Brinter has bootstrapped its growth since 2019, when it launched its first product, and is currently active in more than ten countries, including Germany and the UK.
Customers of the company now include bio and pharmaceutical companies like Nanoform, as well as research organizations like VTT, BEST group at the University of Glasgow, Johannes Gutenberg University of Mainz, the University of Oulu, and the University of Helsinki, whose directors are enthusiastic about the technology’s potential.
For more information, visit www.brinter.com.
Innovestor is an early-stage venture capital investor also offering direct co-investment syndication opportunities and corporate venturing services. It currently manages one of the largest private venture-backed portfolios in the Nordic countries, consisting of over 100 high-tech companies in multiple fields of technology such as cleantech, consumer, enterprise software, health, industrial technologies, and life science, with a total of €123m invested across three funds.
Innovestor aims to be the home of choice for future Nordic success stories. Its core mission is to boost the success and growth of companies by giving access to capital, know-how, and networks by utilizing its unique ecosystem of co-investors and partners.
For further information, visit www.innovestorgroup.com.
Click on Brinter raises 1.2m euros in seed funding to accelerate 3D printing bioscience research and manufacturing for uses that range from personalized drugs to human spare parts for original announcement.